Statin use and outcome after intracerebral hemorrhage: Case-control study and meta-analysis

Neurology

Volumn 76, Issue 18, 2011, Pages 1581-1588

  Biffi, A ^a,b,c   Devan, W J ^a,b,c   Anderson, C D ^a,b,c   Ayres, A M ^a   Schwab, K ^a   Cortellini, L ^a,b,c   Viswanathan, A ^a   Rost, N S ^a,b,c   Smith, E E ^e   Goldstein, J N ^a,b,d   Greenberg, S M ^a   Rosand, J ^a,b,d  

^a Hemorrhagic Stroke Research Group   (United States)

^b Division of Neurocritical Care and Emergency Neurology   (United States)

^c Center for Human Genetic Research   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; WARFARIN;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE CONTROL STUDY; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMENTIA; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FUNCTIONAL ASSESSMENT; GLASGOW COMA SCALE; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MORTALITY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDY; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK;

EID: 79955584262     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182194be9     Document Type: Article

References (30)

1. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med 2001;344:1450-1460. (Pubitemid 32402103)
2. Van Asch CJ, Luitse MJ, Rinkel GJ, Van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and metaanalysis. Lancet Neurol 2010;9:167-176.
3. Donnan GA, Hankey GJ, Davis SM. Intracerebral haemorrhage: a need for more data and new research directions. Lancet Neurol 2010;9:133-134.
4. Karki K, Knight RA, Han Y, et al. Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage. Stroke 2009;40:3384-3389.
5. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg 2004;101:104-107. (Pubitemid 38808468)
6. Jung KH, Chu K, Jeong SW, et al. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 2004;35:1744-1749. (Pubitemid 38823658)
7. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-751. (Pubitemid 36622511)
8. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004;35:2708-2711. (Pubitemid 39458376)
9. Eichel R, Khoury ST, Ben-Hur T, Keidar M, Paniri R, Leker RR. Prior use of statins and outcome in patients with intracerebral haemorrhage. Eur J Neurol 2010;17: 78-83.
10. Gomis M, Ois A, Rodríguez-Campello A, et al. Outcome of intracerebral haemorrhage patients pre-treated with statins. Eur J Neurol 2010;17:443-448.
11. Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Carhuapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care 2008;8:6-12. (Pubitemid 351378099)
12. Leker RR, Khoury ST, Rafaeli G, Shwartz R, Eichel R, Tanne D, NASIS Investigators. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). Stroke 2009;40:2581-2584.
13. FitzMaurice E, Wendell L, Snider R, et al. Effect of statins on intracerebral hemorrhage outcome and recurrence. Stroke 2008;39:2151-2154.
14. Goldstein LB, Amarenco P, Zivin J, et al, Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009;40:3526-3531.
15. Davis SM, Broderick J, Hennerici M, et al, Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006;66:1175-1181. (Pubitemid 43739699)
16. Hanley DF. Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke 2009;40:1533-1538.
17. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004;63:1059-1064. (Pubitemid 39287915)
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-188. (Pubitemid 17189972)
19. Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract 2008;14:951-957.
20. Becker KJ, Baxter AB, Cohen WA, et al. Withdrawal of support in intracerebral hemorrhage may lead to selffulfilling prophecies. Neurology 2001;56:766-772. (Pubitemid 32240097)
21. Rost NS, Smith EE, Chang Y, et al. Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke 2008;39:2304-2309.
22. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11: 1-160.
23. Ramírez-Moreno JM, Casado-Naranjo I, Portilla JC, et al. Serum cholesterol LDL and 90-day mortality in patients with intracerebral hemorrhage. Stroke 2009;40:1917-1920.
24. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453-463.
25. Bosel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 2005;92:1386-1398. (Pubitemid 40389208)
26. Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999;147:253-261. (Pubitemid 29512257)
27. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-8885. (Pubitemid 28350583)
28. Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000;31: 2442-2449.
29. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010.
30. Lu D, Qu C, Goussev A, Jiang H, et al. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma 2007;24:1132-1146. (Pubitemid 47106287)